Trial Search Results
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
To evaluate the efficacy and safety of topical application of MCH 0.04% in a propylene glycol ointment (PG)in patients with stage I or IIA MF previously treated with MCH 0.02% in a PG or AP ointment who did not achieve a complete response.
Stanford is currently not accepting patients for this trial.
- Drug: 0.04% Mechlorethamine gel
- Patients must have completed the treatment phase of the Yaupon Therapeutics-sponsored
Phase II Pivotal study of MCH 0.02% in either the PG or AP formulation and have not
achieved a complete response.
- Pregnant or nursing females, or males and females of childbearing potential, not using
an effective means of contraception
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study